IN8bio Inc. (INAB)
NASDAQ: INAB
· Real-Time Price · USD
3.86
3.74 (3113.99%)
At close: Jun 06, 2025, 3:57 PM
3.60
-6.74%
After-hours: Jun 06, 2025, 05:59 PM EDT
3113.99% (1D)
| Bid | 3.65 |
| Market Cap | 350.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.43M |
| EPS (ttm) | -0.44 |
| PE Ratio (ttm) | -8.77 |
| Forward PE | -0.59 |
| Analyst | Buy |
| Ask | 3.81 |
| Volume | 417,633 |
| Avg. Volume (20D) | 3,103,371 |
| Open | 3.58 |
| Previous Close | 0.12 |
| Day's Range | 2.85 - 3.86 |
| 52-Week Range | 0.10 - 3.86 |
| Beta | 0.18 |
About INAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol INAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for INAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 days ago
-0.97%
IN8bio shares are trading lower after the company ...
Unlock content with
Pro Subscription
3 weeks ago
-9.68%
IN8bio shares are trading lower. The company announced new preclinical data from its INB-619 program at the 2025 American Society of Gene & Cell Therapy Annual Meeting
2 years ago · proactiveinvestors.com
IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatmentIN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan drug designation from the US Food and Drug Adminis...
